Rate Video

COMy Virtual 2020 | Myeloma QoL through induction and maintenance

Heinz Ludwig • 12 May 2020

COMy Virtual 2020

Multiple Myeloma Ixazomib

Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, discusses quality of life (QoL) in patients with relapsed/refractory multiple myeloma and the impact of both induction and maintenance therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

AGMT_MM-1: the oral microbiome as a predictor of PFS in R/R myeloma

Heinz Ludwig • 2 Jun 2020

KRd vs KTd followed by K maintenance or control for high-risk myeloma

Heinz Ludwig • 2 Jun 2020

Novel therapies in myeloma: selinexor, venetoclax, among others

Heinz Ludwig et al. • 27 Jan 2017

Triple combination therapies for multiple myeloma (MM) patients

Heinz Ludwig et al.

Related Videos

Maintenance therapy in young patients with myeloma

Graham Jackson • 5 Mar 2021

BVD in heavily pretreated multiple myeloma

Claudio Cerchione • 3 Mar 2021

#woMMen: network of women in multiple myeloma

Nina Shah • 3 Mar 2021

Frailty subgroup analysis of the MAIA trial

Gordon Cook • 2 Mar 2021